Drugs / rAAV2-hRPE65
rAAV2-hRPE65
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00821340 | Feb 2009 → Jun 2016 | Leber congenital amaurosis | Hadassah Medical Organization | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2-hRPE65 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00821340 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a recombinant adeno-associated virus serotype 2 (rAAV2) vector carrying the human RPE65 (hRPE65) gene” NCT00821340 ↗ |
| Target | RPE65 | “vector carrying the human RPE65 (hRPE65) gene” NCT00821340 ↗ |